sibutramine has been researched along with Polycystic Ovary Syndrome in 12 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Body weight reduction was greater in the sibutramine group." | 9.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| "To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)." | 9.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 9.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS)." | 9.10 | Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. ( Harma, M; Kilic, F; Nazligul, Y; Sabuncu, T, 2003) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 7.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "Obesity is considered important factor contributing development of PCOS." | 5.32 | [Sibutramine administration in polycystic ovary syndrome treatment]. ( Banaś, M; Jochemczyk-Banek, U; Olszanecka-Glinianowicz, M; Zahorska-Markiewicz, B; Zurakowski, A, 2004) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "Body weight reduction was greater in the sibutramine group." | 5.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| "To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)." | 5.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 5.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| "To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS)." | 5.10 | Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. ( Harma, M; Kilic, F; Nazligul, Y; Sabuncu, T, 2003) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 3.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "Obesity is considered important factor contributing development of PCOS." | 1.32 | [Sibutramine administration in polycystic ovary syndrome treatment]. ( Banaś, M; Jochemczyk-Banek, U; Olszanecka-Glinianowicz, M; Zahorska-Markiewicz, B; Zurakowski, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhuang, J | 1 |
| Wang, X | 1 |
| Xu, L | 1 |
| Wu, T | 1 |
| Kang, D | 1 |
| Georgopoulos, NA | 2 |
| Katsikis, I | 5 |
| Florakis, D | 2 |
| Panidis, D | 5 |
| Kandarakis, ED | 1 |
| Koiou, E | 2 |
| Tziomalos, K | 2 |
| Dinas, K | 1 |
| Kalaitzakis, E | 2 |
| Delkos, D | 2 |
| Kandaraki, EA | 2 |
| Vosnakis, C | 2 |
| Armeni, AK | 1 |
| Papadakis, E | 1 |
| Roupas, ND | 1 |
| Sabuncu, T | 1 |
| Harma, M | 2 |
| Nazligul, Y | 1 |
| Kilic, F | 1 |
| Olszanecka-Glinianowicz, M | 1 |
| Zahorska-Markiewicz, B | 1 |
| Jochemczyk-Banek, U | 1 |
| Banaś, M | 1 |
| Zurakowski, A | 1 |
| Lazurova, I | 1 |
| Dravecka, I | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Karabacak, IY | 1 |
| Karabacak, O | 1 |
| Törüner, FB | 1 |
| Akdemir, O | 1 |
| Arslan, M | 1 |
| Lindholm, Å | 1 |
| Bixo, M | 1 |
| Björn, I | 1 |
| Wölner-Hanssen, P | 1 |
| Eliasson, M | 1 |
| Larsson, A | 1 |
| Johnson, O | 1 |
| Poromaa, IS | 1 |
| Diamanti-Kandarakis, E | 1 |
| Nassis, GP | 1 |
| Karkanaki, A | 1 |
| Georgopoulos, N | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
2 reviews available for sibutramine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Antidepressants for polycystic ovary syndrome.
Topics: Antidepressive Agents; Cyclobutanes; Depression; Female; Fluoxetine; Humans; Polycystic Ovary Syndro | 2013 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
7 trials available for sibutramine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
Topics: Adult; Anthropometry; Anti-Mullerian Hormone; Appetite Depressants; Caloric Restriction; Cyclobutane | 2012 |
Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Appetite Depressants; Blood Pressure; Body Constitution; Body Weight; C | 2003 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease.
Topics: Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Female; Fluoxetine; Follicle Stimulating | 2004 |
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Appetite Depressants; Body Weight; Cardiovascular Diseases; Cyclobutanes; Double- | 2008 |
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Topics: Adolescent; Adult; Androgens; Anthropometry; Appetite Depressants; Blood Glucose; Body Fat Distribut | 2008 |
3 other studies available for sibutramine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Female; Humans; Insulin Resistance | 2009 |
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformi | 2011 |
[Sibutramine administration in polycystic ovary syndrome treatment].
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Diet, Fat-Restricted; Female; Humans; Obesity; Polyc | 2004 |